NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research
This article was originally published in The Pink Sheet Daily
Executive Summary
With $230 million from industry and NIH, the Accelerating Medicines Partnership will seek to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.
You may also be interested in...
BIO 2014 Wednesday Round-Up: The Search For Innovation
BIO was abuzz on day three of the conference with excitement over keynote speaker Hillary Clinton as her secret service presence was detected even in the early hours of the day. Meanwhile panelists continued to address the hot topics of collaboration, international growth and oncology.
Viebacher: Drug R&D Future Is In Collaboration, But Safe Harbors Needed
Sanofi CEO says firms and other healthcare stakeholders all need to work together, but “no good deed goes unpunished.”
Drug Development Legislation Targeted For Next Year By Rep. Upton
Energy and Commerce Committee chairman outlines a plan to develop legislation to accelerate pharmaceutical “discovery, development and delivery.”